Additionally, this work aims to evaluate the feasibility, the risk of complications, and the clinical relevance for performing re-biopsy systematically after CRT, in patients with PD-L1 negative LA-NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.